相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An alternative technique for cyclization synthesis, in vitro anti-esophageal cancer evaluation, and molecular docking of novel thiazolidin-4-one derivatives
Ahmed Majeed Jassem et al.
JOURNAL OF MOLECULAR STRUCTURE (2023)
Design, synthesis and evaluation of novel Se-alkylated pyrazoles and their cyclized analogs as potential anticancer agents
Remon M. Zaki et al.
JOURNAL OF MOLECULAR STRUCTURE (2023)
Synthesis, characterization, DFT and biological study of new methylene thio-linked coumarin derivatives
Priya R. Kadam et al.
JOURNAL OF MOLECULAR STRUCTURE (2023)
New 1,3,4-oxadiazoles linked with the 1,2,3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase
Mohamed A. Mahmoud et al.
ARCHIV DER PHARMAZIE (2022)
Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a] indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities
Hesham A. M. Gomaa et al.
BIOORGANIC CHEMISTRY (2022)
Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
Emilie Hafliger et al.
EUROPEAN JOURNAL OF CANCER (2022)
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Lun Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Synthesis, characterization, molecular modeling against EGFR target and ADME/T analysis of novel purine derivatives of sulfonamides
Mashooq A. A. Bhat et al.
JOURNAL OF MOLECULAR STRUCTURE (2022)
Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
Aliaa M. Mohassab et al.
BIOORGANIC CHEMISTRY (2021)
Design and Synthesis of New CDK2 Inhibitors Containing Thiazolone and Thiazolthione Scafold with Apoptotic Activity
Nour E. A. Abd El-Sattar et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2021)
Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies
Deepa R. Parmar et al.
BIOORGANIC CHEMISTRY (2021)
Synthesis, characterization, cytotoxicity studies, theoretical approach of adsorptive removal and molecular calculations of four new phosphoramide derivatives and related graphene oxide
Khodayar Gholivand et al.
BIOORGANIC CHEMISTRY (2021)
The Role of EREG/EGFR Pathway in Tumor Progression
Wan-Li Cheng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking, MD simulation, DNA binding and antioxidant studies
Manish Rana et al.
BIOORGANIC CHEMISTRY (2021)
Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19
Himanshu Rai et al.
MOLECULAR DIVERSITY (2021)
Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors
Ismail M. M. Othman et al.
RSC ADVANCES (2021)
Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity
Fatma A. M. Mohamed et al.
BIOORGANIC CHEMISTRY (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
One-Pot and Two-Pot Synthesis of Chalcone Based Mono and Bis-Pyrazolines
Saba Farooq et al.
TETRAHEDRON LETTERS (2020)
Synthesis, structure elucidation, and in vitro pharmacological evaluation of novel polyfluoro substituted pyrazoline type sulfonamides as multi-target agents for inhibition of acetylcholinesterase and carbonic anhydrase I and II enzymes
Cem Yamali et al.
BIOORGANIC CHEMISTRY (2020)
Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety
Mohammad M. Al-Sanea et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Nuria Garcia-Carbonero et al.
CELLS (2020)
Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
Nashwa M. Saleh et al.
FRONTIERS IN CHEMISTRY (2020)
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard et al.
LANCET (2020)
Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview
Dimitris Matiadis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations
Mohamed Hagar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Y Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Novel 1,2,4-triazole derivatives as apoptotic inducers targeting p53: Synthesis and antiproliferative activity
Hesham A. M. Gomaa et al.
BIOORGANIC CHEMISTRY (2020)
HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability
Tamer A. Elwaie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Investigations on 2-(4-Cyanophenylamino) acetic acid by FT-IR,FT-Raman, NMR and UV-Vis spectroscopy, DFT (NBO, HOMO-LUMO, MEP and Fukui function) and molecular docking studies
M. Habib Rahuman et al.
HELIYON (2020)
QSAR modelling and molecular docking studies for anti-cancer compounds against melanoma cell line SK-MEL-2
Abdullahi Bello Umar et al.
HELIYON (2020)
HOMO-LUMO energy splitting in polycyclic aromatic hydrocarbons and their derivatives
Dongping Chen et al.
PROCEEDINGS OF THE COMBUSTION INSTITUTE (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules
Hesham A. Abou-Zied et al.
BIOORGANIC CHEMISTRY (2019)
Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents
Mohamed Hisham et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Synthesis and antifungal activity of novel pyrazolines and isoxazolines derived from cuminaldehyde
Tao Zhang et al.
JOURNAL OF PESTICIDE SCIENCE (2019)
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
Fabiana Crispo et al.
CANCERS (2019)
ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches
Zhenxing Wu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)
Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma
Chen Liang et al.
CANCER SCIENCE (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Development of encorafenib for BRAF-mutated advanced melanoma
Peter Koelblinger et al.
CURRENT OPINION IN ONCOLOGY (2018)
Pyrazole-pyrazoline as promising novel antimalarial agents: A mechanistic study
Gautam Kumar et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Dual or multi-targeting inhibitors: The next generation anticancer agents
Nulgumnalli Manjunathaiah Raghavendra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Facile synthesis of some pyrazoline-based compounds with promising anti-inflammatory activity
Nahed M. Eid et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B
Philip Hampel et al.
SCIENTIFIC REPORTS (2018)
Recent advances (2015-2016) in anticancer hybrids
Nagaraju Kerru et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
Stefanie Keller et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
Jonas Cicenas et al.
MEDICAL ONCOLOGY (2017)
Review: biologically active pyrazole derivatives
Anam Ansari et al.
NEW JOURNAL OF CHEMISTRY (2017)
Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones
Nagihan Beyhan et al.
ARABIAN JOURNAL OF CHEMISTRY (2017)
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Tiziana Notarangelo et al.
CANCER CELL INTERNATIONAL (2017)
B-Raf Inhibition in the Clinic: Present and Future
Warren Fiskus et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Applications of the Conceptual Density Functional Theory Indices to Organic Chemistry Reactivity
Luis R. Domingo et al.
MOLECULES (2016)
ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Li Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Antinociceptive, anti-inflammatory and antipyretic effects of 1.5-diphenyl-1H-Pyrazole-3-carbohydrazide, a new heterocyclic pyrazole derivative
David do Carmo Malvar et al.
LIFE SCIENCES (2014)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Eltrombopag A Review of its Use in Treatment-Refractory Chronic Primary Immune Thrombocytopenia
Karly P. Garnock-Jones
DRUGS (2011)
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment
Ruchi Tandon et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
QSAR Studies of CYP2D6 Inhibitor Aryloxypropanolamines Using 2D and 3D Descriptors
Partha Pratim Roy et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2009)
Classification of kinase inhibitors using a Bayesian model
XY Xia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The BCL2 family: Regulators of the cellular life-or-death switch
S Cory et al.
NATURE REVIEWS CANCER (2002)
分享论文
